EVALUATION OF CLINICAL OUTCOME OF ANTIPSYCHOTIC THERAPY IN SCHIZOPHRENIC PATIENTS IN PALU – INDONESIA

Schizophrenia is a severe mental disorder characterized by psychotic episodes. The first line of treatment for schizophrenia is the use of antipsychotics that is still subjective. There is still a need for research related to the use of antipsychotics to achieve effective treatment. This study aimed to compare the effectiveness of the First-Generation Antipsychotic (FGA) haloperidol, trifluoperazine and risperidone antipsychotic therapies as Second-Generation Antipsychotic (SGA) based on symptom reduction using the Positive and Negative Syndrome Scale-Excited Component (PANSS-EC) method in patients with acute schizophrenia and relapse hospitalization. This research used a quantitative analysis with a prospective approach where the sampling was conducted using total sampling and the data obtained were analyzed using independent t-test and linear regression analysis. There were 40 out of 120 patients who met the inclusion criteria, consisting of patients in groups of haloperidol, trifluoperazine and risperidone therapies with a therapeutic duration of 3–10 days. The results showed that the average PANSS-EC score of haloperidol medication of 15.35 was greater than that of trifluoperazine medication of 14.42 and the p-value showed no significant difference between the use of FGA, haloperidol and trifluoperazine with p = 0.190 (p> 0.05). The average PANSS-EC score of haloperidol medication (FGA) of 15.35 was greater than that of risperidone (SGA) of 13.6 and the p-value showed that there was a significant difference between haloperidol and risperidone with p = 0.027 (p< 0.05). The multivariate analysis showed p = 0.022 (p< 0.05) which means haloperidol showed the greatest symptom reduction among the three antipsychotic medications.